Nature Cell has won the first-instance trial in a lawsuit seeking to cancel the rejection of product approval for JointStem, a stem cell therapy for which it holds domestic sales rights.

In a voluntary disclosure filed on the 9th, Nature Cell announced that the Seoul Administrative Court had ruled in favor of the plaintiff in the lawsuit seeking the cancellation of the rejection of JointStem's product approval.

This lawsuit was an administrative action seeking to annul the decision made by the Commissioner of the Ministry of Food and Drug Safety on August 5, 2025, to reject the application for manufacturing and sales product approval filed by RNL Regenerative Medicine Research Institute (formerly Albio). The plaintiff was RNL Regenerative Medicine Research Institute, and the defendant was the Commissioner of the Ministry of Food and Drug Safety.

RNL Regenerative Medicine Research Institute filed the administrative lawsuit on September 10, 2025, and on July 9, 2026, the Seoul Administrative Court issued a ruling accepting the plaintiff's claims. Nature Cell explained that this disclosure was made in accordance with the outcome of the first-instance ruling.

The company stated that, in accordance with its disclosure filed on August 19, 2025, it had decided to maintain the domestic sales contract for JointStem until the results of the administrative lawsuit are finalized, and that this matter is hereby replaced by the current disclosure.